博九娱乐网

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It develops sotatercept and ACE-536 that are in Phase II clinical trials to treat anemia and associated complications in patients with 脽-thalassemia and myelodysplastic syndromes, and red blood cell disorders…More; and dalantercept, which is in Phase II clinical trials to inhibit blood vessel formation in tumors through the vascular endothelial growth factor pathway inhibitors.